Last reviewed · How we verify
Nutrestore (GLUTAMINE)
At a glance
| Generic name | GLUTAMINE |
|---|---|
| Sponsor | Emmaus Medcl |
| Drug class | Amino Acid [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Short bowel syndrome
Common side effects
Key clinical trials
- A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia (PHASE3)
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis (PHASE3)
- Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients (PHASE2)
- Efficacy of Modified Si Ni San in Post-Polypectomy Management and Its Impact on Gut Microbiota in Colorectal Polyp Patients (NA)
- Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Striatum and Subthalamic Nuclei in de Novo Parkinsonian Patients and Control Subjects (NA)
- In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nutrestore CI brief — competitive landscape report
- Nutrestore updates RSS · CI watch RSS
- Emmaus Medcl portfolio CI